The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Table 4 Response rate and control rate of sitting systolic blood pressure, and goal attainment rate of low-density lipoprotein cholesterol by each treatment. (Analysis of per-protocol set)

FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, siSBP sitting systolic blood pressure, LDL-C low-density lipoprotein cholesterol, CI confidence interval, SE standard error
^aResponse Rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg or Chang from Baseline of siSBP at Week 8 ≥ 20 mmHg
^bControl rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg
^cGoal attainment rate of LDL-C: proportion of the subjects whose LDL-C < 100 mg/dL (high risk), LDL-C < 130 mg/dL (moderate high or moderate risk), LDL-C < 160 mg/dL (low risk)
^dComparison between combination therapy and monotherapy was analyzed by Logistic regression model adjusted for baseline values, age, and gender, smoking status

ISSN: 2050-6511